Searched for
GBR 830
Real activity will start from Q4 of this year: Glenn Saldanha, GlenmarkFrom here on, the US sales should grow back and start trending upwards.- Hold Glenmark Pharmaceuticals, Rs 530: EdelweissHold Glenmark Pharmaceuticals Ltd. at a price target of Rs 530.0 .
- Over next 12-15 months, expect a lot of licensing activity: Glenn Saldanha, Glenmark“Everything is contingent now on getting new product approvals on time.”
- Glenmark Pharma releases investigational skin findingsGlenmark Pharma President and Chief Medical Officer Fred Grossman said atopic dermatitis can have a severe impact on quality of life and th...
- Sensex drops over 500 points, Nifty below 7,700; Amtek Auto plunges 12%, Cipla up 3%The S&P BSE Sensex plunged over 200 points in trade on Friday tracking muted trend seen in other Asian markets. The fall in the index was l...
- Fourteen stocks in focus in Friday's tradeIndian markets are expected to trade in a range. Here is a list of fourteen stocks which are likely to remain in focus today.
- Glenmark Pharmaceuticals completes phase I clinical trials for antibodyGlenmark Pharmaceuticals has completed the clinical phase I studies for its novel monoclonal antibody 'GBR 830' for treating autoimmune dis...
- Glenmark bullish on drug discovery pipeline, eyes partnershipsPain, inflammation and oncology are the therapeutic areas currently the drug maker is working on, said Glenn Saldanha, Chairman & Managing ...
- Sensex rangebound; top fifteen stocks in focusThe Nifty was at 7,728.70, up 13.90 points or 0.18 per cent. It touched intraday high of 7,731.45 and a low of 7,708.90 in trade today.
- Fifteen stocks in focus in Friday morning tradeIndian markets are expected to trade in a range. Here is a list of fifteen stocks which are likely to be in focus today.
- Glenmark Pharmaceuticals' new molecule enters human trialsGlenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 is entering human trials.
- Glenmark opens new manufacturing facility in SwitzerlandGlenmark Pharmaceuticals opened a new manufacturing facility in Switzerland for supply of clinical trial material.
- Glenmark initiates studies to develop new molecule 'GBR 830'Glenmark Pharmaceuticals initiates studies to develop a new molecule 'GBR 830', which could treat diseases like Arthritis (RA) and bowel di...
Load More
